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Summary.-The Medical Research Council has for some years encouraged collabora-
tive clinical trials in leukaemia and other cancers, reporting the results in the medical
literature. One unreported result which deserves such publication is the develop -
ment of the expertise to design and analyse such trials. This report was prepared by
a group of British and American statisticians, but it is intended for people without
any statistical expertise. Part I, which appears in this issue, discusses the design of
such trials; Part II, which will appear separately in the January 1977 issue of the
Journal, gives full instructions for the statistical analysis of such trials by means of
life tables and the logrank test, including a worked example, and discusses the inter-
pretation of trial results, including brief reports of 2 particular trials.
Both parts of this report are relevant to all clinical trials which study time to
death, and would be equally relevant to clinical trials which' study time to other
particular classes of untoward event: first stroke, perhaps, or first relapse, metastasis,
disease recurrence, thrombosis, transplant rejection, or death from a particular
cause. Part I, in this issue, collects together ideas that have mostly already appeared
in the medical literature, but Part II, next month, is the first simple account yet
published for non-statistical physicians of how to analyse efficiently data from
clinical trials of survival duration. Such trials include the majority of all clinical
trials of cancer therapy; in cancer trials, however, it may be preferable to use these
statistical methods to study time to local recurrence of tumour, or to study time to
detectable metastatic spread, in addition to studying total survival. Solid tumours
can be staged at diagnosis; if this, or any other available information in some other
disease is an important determinant of outcome, it can be used to make the overall
logrank test for the whole heterogeneous trial population more sensitive, and more
intuitively satisfactory, for it will then only be necessary to compare like with like,
and not, by chance, Stage I with Stage III.
CONTENTS
Many of these sections may be read out of context, or skipped while reading the
main report. The sections on Analysis (Part II), which describe how to draw life
tables and to compute P-values by the logrank test, can be used in isolation from the
earlier sections on Design (Part I).
Requests for reprints to: R. Peto, Radcliffe Infirmary, Oxford, England; or to: M. C. Pike, University
of Southern California School of Medicine, Los Angeles, California 90033, U.S.A. Reprints of both parts
will be sent to those who request reprints of either part.
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INTRODUCTION
1.-General aims
Many clinical trials compare survival
duration among cancer patients randomly
allocated to different treatments. There
has been much investigation in the statis-
tical literature of possible ways of inter-
preting the data from such trials, the
surprising outcome of which has been the
discovery that two techniques (life table
graphs and logrank P-values), which are
so simple that they are easily mastered by
non-statisticians, are commonly more
accurate and more sensitive than any of
the elaborate alternatives that have been
considered. Part II of this report, which
will appear in the next issue, describes
these two techniques in sufficient detail for
them to be performed entirely without
statistical guidance. Part I, in this issue,
explains, without using specialized
statistical language, statistical ideas about
numbers of patients, withdrawals, strati-
fication and so on. So that no reference
to any other papers or tables should
be necessary, even such commonplace
statistical things as chi-square (in Part II)
and random number tables are supplied
and explained.
This report addresses itself to the more
quantifiable aspects of clinical trials-
treatment comparisons, treatment
toxicities, treatment effects in special
subgroups, recognition of prognostic
features, and so on-while ignoring the
important indirect benefits of clinical
trials. For example, there is variation in
clinical practice between different hospi-
tals, and in a collaborative trial this is
likely to be discussed, leading perhaps to a
valuable exchange of ideas and to some
improvements. Even if this does not
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occur, the imposition of a treatment
schedule actually confers a freedom from
having to devise separately each detail of
treatment for each different patient,
which may make patient management
easier and, perhaps, more successful.
Another indirect benefit is that a pattern
may be noticed in the data which, even
if it could well be due just to chance,
suggests a line of thought which proves
fruitful in this, or some future, study.
It would be unfortunate if our later
emphasis on definite answers and large
trials were to dissuade prospective
organizers from planning a small clinical
trial in a hitherto little-studied condition
if the alternative is no trial at all.
However, most small trials could, with
profit, be larger if the organizers attempted
collaboration with other hospitals.
The detail needed to explain a concept
such as the P-value to readers who are not
clear about its true meaning and useful-
ness would be tiresome to readers who are,
and so both parts of the report are divided
into sections, each preceded by a sentence
summarizing it, so that the whole thing
can be looked through without wasting
time reading sections which are already
understood: likewise, because of the con-
tents list and section summaries, particu-
lar details (e.g. arithmetic techniques)
should be easy to refer to, if only these are
wanted. The report may help physicians
to dispense with specialized statistical
advice on some occasions, and make more
critical use of it on others. It should also
be of interest to statisticians who have not
yet specialized in such data. For statistical
readers, a series of " statistical notes " is
referred to throughout the text. These are
collected together at the end so as not to
distract the general reader from the main
text, which is self-sufficient without them.
The collective noun for statisticians is
said to be " A variance of statisticians ",
and so, although the whole report is
largely consensual, some of us may differ
from it in certain particulars, as may
some members of the committee to
which it is addressed.
2.-Event times
Whatever index of failure is of interest,
one should not only count how many
people " fail " but also see when they
failed.
A common form of clinical trial
compares treatments which are intended
to prevent or delay death from a particular
disease. If the course of the disease is
very rapid (e.g. acute liver failure) and it is
unimportant whether a dying patient
lives a few days longer or not, a count of
the numbers of deaths and survivors on
each treatment is all that is required.
However, if (as with most forms of neo-
plastic disease) an appreciable proportion
of the patients do die of the disease, but
death may take some considerable time, it
is possible to achieve a more sensitive
assessment of the value of each treatment
by looking not only at how many patients
died, but also at how long after entry they
died. The best way of doing this is quite
simple, but it is easy to overlook when
first confronted with the problem. This
also applies to any clinical trial which is
concerned with the prevention of some
other untoward " event " (or " endpoint ")
that may eventually affect some or all of
the patients. If these events may not
occur for some time after starting treat-
ment, it is worth looking at the times at
which the events occur as well as counting
the number of events in each group of
patients. The sort of untoward events
which could be studied in such a clinical
trial might be myocardial infarctions,
leukaemia relapses, strokes, metastatic de-
velopments, death from one of a certain
set of specified causes (ignoring deaths
from other causes), transplant rejection
episodes and so on. In each of these
studies, it is usually possible to do a more
informative analysis than a simple tabu-
lation of the numbers of patients on each
treatment who suffered the event of
interest. Whether this event is death or
local solid tumour recurrence or some-
thing else, the design principles and
statistical methods are virtually the same:
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we observe and make use of the times at
which each patient who suffers the event
of interest (first) does so.
DESIGN
3.-Numbers of patients required
Study of a few dozen patients can in
most cases detect an ideal treatment
which prevents more than two-thirds
of the deaths, but more realistic effects,
such as preventing about one-third of
the deaths, requires well over 100
patients to be detected.
The essence of performing a successful
clinical trial is to enter a sufficient number
of patients. In theory, a small trial may
produce significant results; a total of 10
patients, 5 given one treatment and 5
another, could yield a result which is
statistically significant at the 1% level*,
if in one group all 5 die and in the other
group all survive. But, in practice, trials
comparing survival times among only a
few patients often just confuse issues or
lead subsequent research in fruitless
directions, unless there is an all-or-nothing
difference between the effects of the treat-
ments being compared, as apparently, for
example, in Willoughby (1974).
There is sometimes a need for a small
pilot trial in which treatment schedules
are adjusted to acceptable levels of
cytotoxicity and of toxicity to the patient
before they can be tried out in a large
trial, but uncontrolled preliminary trials
to get a rough idea of the long-term
efficacy of a certain treatment prior to a
large trial can be as misleading as any
other small trial (Chalmers, 1975).
Clinical trials are not as sensitive as
one would suppose to quite substantial
differences between treatments, because
random differences between different
groups of patients are so much larger than
one might expect (Fig. 1). In clinical
trials of time to death (or of the time to
some other particular " event "-relapse,
metastasis, first thrombosis, stroke, recur-
rence, or time to death from a particular
cause), the ability of the trial to distin-
guish between the merits oftwo treatments
depends on how many patients die (or
suffer a relevant " event ") rather than
on the number of patients entered. A
study with 100 patients, 50 of whom die,
is about as sensitive as a study with 1000
patients, 50 of whom die. The ability of
30 GET ONE
TREATMENT
14 DIE
16 SURVIVE
99tf9lit9
FIG. 1.-In 10% of the small clinical trials
which compare equivalent treatments, re-
sults at least as extreme as those illustrated
here will arise just by chance. This will
be due to chance allocation of more of the
patients who would have died anyway to
one particular treatment.
a trial to distinguish between 2 treatments
also depends, obviously, on how extreme
the difference between the 2 treatments is.
The exact dependence on the magnitude
of this difference and on the number of
patients who have to die (or suffer a
relevant " event ") is described in Appen-
dix 1.
Before examining Appendix 1 care-
fully, let us consider 2 hypothetical
situations. First, suppose there are 2
treatments to be compared, that we are
interested in their effects on death rather
than on any other endpoint, and that the
better treatment prevents or substantially
delays one-third of the deaths that would
occur on the other treatment: in other
* This would be true using almost any statistical method. The exact meaning and practical utility of
significance levels (" P-values ") is discussed later.
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words, the death rate ratio (better: worse)
is 2: 3. The better treatment is thus a
very important medical advance over the
other treatment, and it would be extremely
important that so marked a therapeutic
improvement should be clearly demon-
strated and widely accepted. Unfortu-
nately, advances in therapy as marked as
this are not common, and few of the
organizers of the many hundreds of
clinical trials currently in progress are
lucky enough to be studying a 2:3 ratio
in mortality.
In the second hypothetical situation,
we shall suppose that the improvement is
even better, and that the death rate ratio
is 1: 3. In other words, suppose we have
discovered an excellent treatment which
prevents or substantially delays most of
the deaths which would occur on the other
treatment. This is probably an unrealistic
hypothesis, but it will help illustrate the
limitations of clinical trials.
Now let us refer these 2 situations to
Appendix 1, to discover how large a
clinical trial must be to demonstrate
treatment differences in these 2 hypotheti-
cal instances. In the second hypothetical
situation, where the death rate ratio is 1: 3,
the sort of small trial that a single large
centre might organize alone, in which a
few dozen patients are randomized and
20 of them die, has an even chance of
demonstrating a significant (at 5%/ level)
difference (and, therefore, an even chance
of failing to do so). If enough patients
were randomized for 40 deaths to be
observed, however, there would be an 80%
chance of a statistically significant result,
and, even if the result happened unfortu-
nately not to be statistically significant,
the group given the better treatment
would almost certainly have fared sub-
stantially better than the other group.
What of the more realistic situation,
in which the death rate ratio is only 2:3?
This would still be of great medical
importance, but the table in Appendix I
indicates that, even if several centres
cooperated, randomizing enough patients
for 100 deaths to be observed, there would
be only an even chance of a statistically
significant difference being seen.
Although a statistically significant dif-
ference might turn up in a trial in which
100 deaths occurred, it might well not
turn up in a trial in which well over 100
deaths occurred: to be safe, we would have
to plan a trial involving maybe 200 deaths,
which is, by current standards, a large
clinical trial.
If we were interested in preventing
some other sort of " event ", e.g. tumour
recurrence, and the event ratios on the 2
treatments were 1: 3, then again we
should need to plan a clinical trial in
which we anticipated that 20-40 people
would suffer such an event, while to
detect a 2: 3 ratio we should plan for
100-200 people to do so, and would need a
trial intake of hundreds (or, if the events
are rare, thousands) of patients. For
such a trial, collaboration between several
different centres is likely to be needed.
The practical conclusion is that clinical
trials can easily monitor death rate ratios
between 2 treatments which are 1: 3 or
better, but that detection of anything less
extreme than 2:3 is very difficult. These
summary ratios are very important, and
should be written on the shirt-cuffs of all
trial organizers, as attempting to study a
difference which could not plausibly be as
extreme as 2: 3, by a clinical trial, is a
common mistake.
Our experience is that treatments
which halve the rate of untoward events
other than death are sometimes devised,
and that the efficacy of such treatments
may, therefore, be demonstrated by a
single good clinical trial, but that treat-
ments which prevent or substantially
delay one-third of all deaths are very
rarely devised. For example, cranio-
spinal irradiation of children in remission
from acuite lymphoblastic leukaemia al-
most eliminated relapse due to leukaemic
proliferation in the meninges and brain
(reducing the event rate to less than one-
third of what it was before) but because
many children died for other reasons, the
overall death rates were not initially
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reduced very much. Clinical trials in
which the influence of treatment on time
to death is of prime interest should
rarely be undertaken unless either
there is some hope that the death rate
can be halved, or the trial will be able to
continue until at least 100 patients have
died, which will usually require the
admission of well over 100 patients.
There are exceptions, of course (the chief
one being when the disease is so rare that
large trials are impossible, even if many
hospitals collaborate), but it is unusual
for the comparison of the times to
death of a smaller number of patients
to be of much value, unless (as might be
the case if no large series of such patients
had yet been reported) the chief point of
the trial is not the comparison of 2 treat-
ments but rather the study of the natural
history of the disease. Moreover, the
patients may need to be entered over a
reasonably short time, if the trial is not to
be overtaken by results from other trials.
Because of this, in all but the commonest
diseases, no one physician or even hospital
department will be able to complete alone
a successful trial studying survival dura-
tion. Cooperation between independent
physicians in different hospitals is often
essential. *
It would undoubtedly be better if the
organizers of most of the hundreds of
different small trials currently in prepara-
tion or progress at single centres around
the world attempted to secure the col-
laboration of colleagues at other centres
in randomizing patients into their trials.
Sometimes quite a small organizational
effort can double or more than double the
size of a given trial by recruitment of
other centres at which, otherwise, no sort
of a trial would have been running. It is
wrong for research-oriented centres to
disdain such collaboration from centres
which are not research-oriented, even if the
standards of medical management are pre-
sumed not to be quite as good as at the
research-oriented centre. In fact, since
the success of a trial depends so strongly
on the numbers of patients randomized, it
should perhaps be emphasized when
soliciting collaboration that all physicians
who do collaborate wholeheartedly will be
full co-authors of any eventual publica-
tions.
4.-What treatment schedules should be
compared?
A positive result is more likely, and a
null result is more informative, if
the main comparison is of only 2
treatments, these being as different
as possible.
The chief point is that the question
answered must be the most important
question the investigators can think of,
which they could answer by a clinical
trial. A lesser study of an important
question is usually of more value than an
excellent study of a trivial question.
Next, discover who else is answering the
same question; the EORTC and UICC
keep current lists of the hundreds of
cancer trials currently in progress. The
American NCI keeps lists of all current
trials of immunotherapy (Windhorst,
1976), and has commissioned a com-
pendium which is supposed to be updated
every 3 months of all clinical trial proto-
cols, including those on the European
lists; the first issue of this has just
appeared (Smithsonian Corporation,
1976). Become familiar with these lists
at the earliest possible stage of your
planning, but remember that many listed
trials are so small or poorly controlled
that the questions they ask may still
* In such cooperative studies, there is no assumption that the type of patient or quality of management
at one centre is comparable with that at another centre. It is only assumed that if a treatment is of medical
value, then this will be true at every centre, and although the treatment difference actually observed at
an individual centre may be randomly obscured or even reversed, the overall sum of all the separate treat-
mant differences, one from each centre, should point in the right direction and the separate differences
should thus reinforce each other, even if most, or perhaps all, of the separate differences are not individually
significant.
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need to be answered by a large, randomized
trial.
Onlv a very limited time may be
available before results of other trials
intrude, and lead to strong pressures to
modify treatment details or even com-
pletely to abandon certain schedules. It
is thus usually more efficient to compare
only 2 treatment schedules in any trial,
since this gives the maximum chance of
being able to draw some definite con-
clusions before the schedules have to be
modified. (In this context, of course, 1
of the 2 treatment schedules might be " no
treatment ".)
Moreover, these 2 treatments must be
sufficiently different from each other for it
to be medically plausible that the death
rate (or the rate of whatever type of event
is of chief interest) on one could well be very
substantially lower than on the other. If
it is not plausible that a slight difference
in radiotherapy fractionation or in drug
dosimetry could have a substantial effect
on the outcome, then clinical trials of such
slight differences are unlikely to be useful.
We are not arguing that the answer has to
be known before the trial could be
designed, of course-merely that treat-
ments that could well differ substantially
should be compared.
Many clinical trials yield null results
(i.e. they find no statistically significant
differences between the groups of patients
given different treatments) and it is a
mark of good trial design that a null
result, if it occurs, will be of interest. If
you are trying out a new drug, give the
biggest dose of it that you safely can, so
that nobody can say, if you get a negative
result, that if only you had given more it
would have worked. (A drug trial is
always a trial of the drug in the particular
dose and manner given, not a trial of the
drug per se.) If you are checking other
people's work, repeat their protocols
exactly, so that they cannot suggest that
minor irrelevant differences between the
conduct of your trial and theirs were
actually relevant. If you are testing
whether a reduction in the amount of
therapy is possible, reduce the therapy as
much as you dare, and so on. Negatives
in such trials are of much wider interest
than negatives in less extreme comparisons.
When designing a trial, one usually has the
possibility of discovering a clear difference
foremost in one's mind, but it is a useful
exercise to force oneself to answer the
questions " What medical value will these
results have if both treatment groups fare
equally well? Could the trial design be
altered to make a negative result, if it
occurs, even more valuable? "
An agent which is therapeutically
effective when given in one particular
way may be much less effective when
given at a different dose level or with
different intervals between doses. This
makes it difficult to use results from a
clinical trial to discover which of 2
different agents is absolutely best, for
one of the agents might have been better
if used differently. (This difficulty can
be avoided if each agent is sufficiently
well understood for the investigator to
be confident that it is being used opti-
mally, or almost optimally, but this is
unusual.) In the particular case of a
trial intended to discover the better of 2
cytotoxic anticancer agents, both of
which damage normal, as well as neo-
plastic, cells, the agent to be preferred is
usually the one which for a given degree
of damage to normal cells produces the
greater anticancer effect. This agent can
usually only be identified by a clinical
trial if the schedule for each agent
produces a similar degree of damage to
normal tissue. When testing actinomycin
versuis vincristine, therefore, perhaps the
total doses to be given should not be
specified in milligrams, but rather in terms
of the approximate degree of myelo-
suppression to be attained. Likewise,
when comparing 2 forms of radiotherapy,
perhaps each should be given until a
certain degree of damage is observed in
adjacent normal tissue. When designing
(or interpreting) a trial which compares 2
different anticancer agents, this question
should be carefully considered.
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4A.-Secondary studies
So far, we have argued that a question
is more likely to be successfully answered
by a clinical trial if it can be answered by
comparing just 2 alternative treatments
and no more, those treatments being as
markedly different as possible. However,
if 2 largely unrelated questions can be
posed (e.g. " Do platelet transfusions help
remission induction? " and " Does regular
maintenance cytotoxic therapy during
remission help? ") then both can be
answered by a single clinical trial. At
presentation, the patients are randomized
as to whether or not they get platelets, and
those who achieve remission are then
randomized as to whether or not they get
maintenance therapy. Actually, more
than 2 questions can be answered at once:
for example, we could have, in addition,
randomized the patients who achieved
remission, so that half received immuno-
therapy and half did not (so one-quarter
would have received immunotherapy and
maintenance, one-quarter would have
received immunotherapy and no main-
tenance, etc.).
If a clinical trial is large enough to be
scientifically worthwhile, the efforts of
recruiting the large number of patients
entered into it, and of following them up,
are substantial. The extra scientific pay-
off from answering extra questions is
usually well worth the slight extra organiz-
ational effort involved in multiple random-
ization, as long as you don't try to
answer 2 very strongly related questions
in the same trial. Once a substantial
clinical trial is definitely to be undertaken
to answer one particular important ques-
tion, explicit attention should next be
directed towards identifying other, prob-
ably lesser, questions that the trial could
easily answer concurrently by multiple
randomization, as long as the trial is not
made so complex that potential collab-
orators are deterred from participation in
this (or future) trials.
Trials may also be used as a source of
information about the natural history of
a disease, quite independently of the
therapeutic question which is being asked,
perhaps by measuring or recording some-
thing at presentation and studying its
correlation with some other recorded
factor, or with time to death or to what-
ever endpoint is of interest, or perhaps by
making serial records of something so that
its pattern of change over several months
can be studied. It may be wise to make
such studies optional, in that some centres
will do them for all patients while other
centres will not do them at all, otherwise
the number of patients randomized may
be reduced.
Finallv, the commonest reason for
deviations from schedule in cancer trials
is probably treatment toxicity, neces-
sitating that less than the specified dose
be given or that courses of treatment be
delayed. Specification of schedules
should therefore include details of what
to do if undue toxicity emerges: practic-
able, flexible schedules avoid many " devi-
ations " and are more relevant to real
medical practice, as long as the reasons for
" flexibility " are clearly formulated.
5.-Significance levels (" P-values ")
"P 0-05 " does not mean " the prob-
ability that the treatments are equiva-
lent is 0 05 ".
There are fewer sources of error and
bias in a randomized study than in a
non-randomized study, but even with
proper randomization misleading results
can emerge.
If a group of patients treated one way
does better than another group which was
treated in another way, there are 2
possible explanations for this: either the
first group got better treatment, or the
first group contained disproportionately
many patients who would have done well
anyway, even if they had been treated in
exactly the same way as the second group.
Unfortunately, division of patients into 2
treatment groups by randomization is no
guarantee that the 2 groups have equal
proportions of patients with good and
bad prognoses, and so, even in a random-
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ized trial, spurious differences between
treatments will sometimes arise. The
whole elaborate clinical trial machinery
of randomization, objective assessment,
avoidance of losses to follow-up, and so on,
however, ensures that if a substantial
difference emerges between the average
outcomes in the 2 treatment groups, then
we can calculate the probability of getting
a difference at least as substantial as this
by chance alone if the 2 treatments are in
fact equivalent. This probability is called
the "significance level ", or " P-value ".
Even if the 2 treatments are exactly
equivalent, our random allocation may,
by chance alone, put more of the good-
prognosis patients on to one treatment
than on to the other. The exact meaning
of the familiar abbreviation " P < 0 05 "
is thus " the patients in one treatment
group have fared better than the patients
in the other. If there is no difference
between the medical effects of the 2
treatments and the only cause of dif-
ferences between the treatment groups is
the chance allocation of more good-
prognosis patients to one group than to
the other, then the chance of one treatment
group faring at least this much better than
the other group would be less than 0 05,
i.e. less than a 1 in 20 chance. "
It is worth the effort of understanding
this convoluted statement, since the logic
of it contributes to so much modern medi-
cal research. (It does not, for example,
mean that the probability that there is no
difference between the treatments is 0.05.)
A significance level is, it may be seen, an
extremely indirect answer to a physician
who simply wants to know which treat-
ment works best (especially since events
with probability less than 0 05 are really
quite plausible: throwing double 6 with a
pair of dice, for example), but it is better
than no such answer at all. To calculate
the significance level, it is not necessary
that exactly similar proportions of patients
with bad, medium and good prognoses
were allocated to each treatment. What
is necessary is merely that the probability
of a trial patient getting one or other
treatment be independent of whether that
patient has a bad, medium or good
prognosis, and that the standard of
assessment of success or failure be in-
dependent of treatment. This means
that stratified allocation (which is dis-
cussed later) is not necessary, but ran-
domized allocation is.
6. Further reasons for large trials
k given P-value in a large trial is
usually stronger evidence that the
treatments really differ than the same
P-value in a small trial of the same
treatments would be.
There are hundreds of well-conducted
clinical trials now in progress, which are
comparing 2 essentially equally effective
treatments. Unfortunately, at least 1
in 20 of these null trials will report a mis-
leadingly significant (P < 0.05) difference.
Conversely, many of the trials which are
now comparing 2 genuinely different
treatments will not observe a "significant "
difference. How, then, should claims of
" statistical significance " be assessed,
when it is common experience that many
early claims are later refuted? In classi-
cal statistical theory, only 2 criteria the
P-value and the intrinsic plausibility of
the claim which the P-value supports-
are supposed to be balanced, but in
assessing these to decide whether or not
the 2 treatments really differ at all, the
size of the trial is an additional, in-
dependent, third criterion. Let us con-
sider this in the context of a trial where a
new treatment is being compared with, as
control, a standard treatment.
Nowadays, for every trial that com-
pares 2 treatments which are substantially
different, there are probably 5 to 10
" null " trials in progress comparing 2
treatments which are almost equally
effective. Moreover, even the " substan-
tial" differences are by no means so
substantial that small trials can reliably
detect them: it might be, for example,
that when 5000 of the control patients are
dead, only 3300 of the patients receiving
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TABLE I.-Numbers of Trials Currently in Progress that will be Statistically Significant
Planned trial size
(unless an early
treatment differ-
ence stops the
trial when smaller
than this)
About 250 deaths
(i.e. an entry of
some hundreds of
patients)
About 25 deaths
(i.e. an entry of
some dozens of
patients)
Expected proportion dead
in one treatment group
when half the patients in
the other group are dead
50%
(no real difference)
33%(treatments really differ)
50%
(no real difference)
33%(treatments really differ)
Postulated no. of
such trials now in
progress world-
wide
100
20
1000
200
Given these postulated numbers
in progress, approximately how
many of them will be:
A
(b) Significant
(a) Non- at P< 0 05 or
significant better
95
(right)
1
(misleading)
950
(right)
150
(misleading)
at least 5*
(misleading)
19
(right)
at least 50*
(misleading)
50
(right)
* Even the most rigorously designed, executed and analysed studies have a 1 in 20 chance of a P < 0 05
false positive. The less rigorous the study, the greater the chance of a false positive, and in practice
perhaps 10%/ or more of all studies yield such false positives. A major error, premature termination, is
discussed in Statistical Note 1 on page 610.
the new treatment would be expected to
have died. A difference of this magnitude
has over 95% chance of being detected
in a trial in which hundreds of patients are
randomized and about 250 of them die,
but only a 25% chance of being detected
in a small trial in which dozens of patients
are randomized and about 25 of them die.
We need now only to postulate a few
reasonable numbers to see the effects of
this situation (Table I). Three immediate
consequences of the numbers in Table I
may be discerned:
(i) A large proportion (pehaps even
the majority) of reports of statisti-
cally significant treatment dif-
ferences in small trials are mis-
leading, and no real differences
exist. (This is not true of trials
which are planned to be large*.)
(ii) If a small trial compares a new
treatment which is so effective
that it prevents one-third of the
deaths with a control treatment
then it will probably fail to reach
statistical significance. (This is
not true of a large trial.)
(iii) A serious bias arises because most
of the interesting therapeutic ques-
tions are being studied simul-
taneously by many trials: for
example, 400 are in progress,
studying the immunotherapy of
malignant disease (Windhorst,
1976). Any trials, large or small,
in which patients given the new
therapy fare significantly better,
will be published and publicized,
but few trials which discover no
difference will achieve wide atten-
tion, especially if they are small.
The UICC are attempting to
rectify this situation by publishing
each year, in their Technical
Report series, a list of all trials
currently open or recently closed,
specifying reasons for closure.
Despite this effort, the literature
remains biased. It is an inevit-
able bias, but one which can be
circumvented to some extent by
restricting attention to trials so
large that they would be published
whether or not a difference was
observed. A further consequence
* However, trials comparing genuinely different treatments which are planned to be large may yield
such striking results when still small that they are stopped and published. This would increase the number
of genuine differences in published small trials at the expense of the number of genuine differences in
published large trials. The effect is substantial only if the real treatment difference is sufficiently extreme
for there to be a good chance of its detection in a small trial, which will often not be the case.
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of publishing only the trials where
large differences are apparent is
that, when it is claimed that a new
treatment is better, even if this
claim does eventually turn out to
be true, the magnitude of the
benefit associated with the new
treatment will almost always be
over-estimated by the first few
published studies.
In summary, collaboration between
centres, which are now independently
organizing small trials to answer similar
questions, would be greatly in the general
interest, as long as the large trials thus
initiated are competently organized.
Once a moderately large trial has been
organized, however, how extreme must
the P-value be before the results can be
believed?
7. Prior opinions
It is proper to combine prior opinion
and knowledge with P-values to guess
the truth.
Consider a publication describing a
moderately large randomized clinical trial,
organised by reputable investigators,
which purports to show that a certain
treatment is useful. Suppose that, before
you saw these results, you already thought
that this treatment probably worked.
Even if the reported difference is not
statistically significant, you would become
more definite in your opinion, while if a
P-value of 0U05 is reported, there would be
almost no doubt left in your mind that this
treatment works.
Suppose, instead, that before you saw
these results you had no opinion, but on
reflection the claim seems reasonable (e.g.
systemic chemotherapy in Stage II breast
cancer). Now, a P = 05 result would
not in itself be convincing, although it
would make you more receptive to future
such claims; a P = 01 result would be
difficult to dismiss; while 'a P < 0 001
result would be extremely convincing.
Suppose, finally, that, had your opinion
been sought before reading the published
report, you would have thought that
there was little prospect of such a treat-
ment being of value. Now, a P 0-05
result would leave you almost as sceptical
as before; and although a P < 0001
result would change your mind, you would
still retain a secret little doubt.
Different investigators will not, of
course, agree as to what is plausible, and
so in published reports more emphasis is
often placed on P-values (P-values should
be subject to public agreement) than on
opinions. However, different readers will
judge a claim differently, and the hetero-
geneity of their prejudices is a useful
safeguard against collective error.
Conversely, there are many instances
when people should have been guided
by positive or by null findings in
randomized trials, but were not; the
cardiotoxicity of certain oral hypo-
glycaemic agents has been strongly
suggested by a large randomized trial,
but this finding is still dismissed by many
diabetologists. They may be right to
dismiss it, but, if they are not, many
avoidable deaths are being caused.
8.-Non-significant differences
What may be inferred if there is no
statistically significant difference be-
tween two treatments?
An exact answer requires statistical
expertise, but adequate approximations
are easy to construct. Two things are
important: the size of the trial, and what
was observed in it (approximate equality
or an appreciable difference which never-
theless was not significant).
In a small trial, a non-significant result
yields almost no information, except that
if there was an appreciable difference then
the apparently better treatment is un-
likely to be much worse than the other
treatment, although it could well be a
little worse. (This may be a sufficient
answer, if the apparently worse treatment
is very toxic or expensive.) If approxi-
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mate equality was observed in a small
trial, there could still easily be a 2-fold
disparity between the death rates on the
2 treatments, while if one did appreciably
better than the other, then maybe there
is no real difference, or maybe the
apparently better treatment is 2, 3 or 4
times as good. Such unreliable infor-
mation is of much less value than data
from a larger study would have been.
In a large trial, involving about 250
deaths, if approximate equality was ob-
served, then there could still be a 20%
treatment difference in either direction,
while if one group fared appreciably
better, then the treatment they received
might really be no better, or it might
really prevent 10, 20 or 3000 of deaths.
Thus, even null results from large trials
have considerable uncertainty attached
to them, although they are of more
value.
Such null results are so vague, and
significant results indicate the magnitude
of any real difference that may exist so
imprecisely, that it should cause no
surprise, when several studies of the same
question are compared, to discover that
some are highly significant while others
are nowhere near statistical significance.
We have already seen that " significantly
different " is not synonymous with " dif-
ferent "; still less is " non-significant "
synonymous with " identical ". In fact,
no statistical argument can ever demon-
strate 2 treatments to be identical; all one
can do is to say what range of differences
is consistent with the observed data.
9.- Treatment allocation ratio 1: 1 or 2: 1?
Unequal allocation may be best.
In any clinical trial report in which a
new treatment is claimed to be effective,
readers will assess the claim, not only in
the light of the comparison with the trial
control group, but also by comparison
with their own experience and ideas as to
what is plausible. This is, of course,
right and proper; but for comparison with
other data, the larger the group who
received the new treatment the better.
It may, therefore, be advisable, when
comparing " new " with " old ", to ran-
domize not in the ratio 50:50, but perhaps
in the ratio 60:40 or 67:33 (2:1). Ran-
domization in the ratio 2: 1 may also be
preferred, if one treatment is much more
expensive or inconvenient than the other.
The chance of obtaining a statistically
significant difference between the 2 treat-
ments is not reduced much, as long as the
chosen ratio is less extreme than 70:30*,
and the increase in the size of the " new "
group that can be reported may easily
outweigh this power loss.
Suppose 2 minor variants of a new
treatment are possible, and we adopt
equal 3-way randomization between con-
trol and the 2 variants. Comparison of
the control patients with all patients
given the new treatment, irrespective of
which variant they received, gives us an
efficient 2:1 trial of whether the new
treatment is any better than control.
If it is, then as a slight bonus we already
have a small randomized study comparing
2 variants of it.
Alternatively, if when arranging a
collaborative trial between 2 treatments
there is a definite difference of opinion
about a lesser detail of one of them,
collaboration may be saved by the
proposal of 3-way equal randomization at
all centres, which will still yield a useful
2:1 study of the main question.
10.-Randomized controls or " historical
controls "?
Assessing a new treatment solely by
comparison with past experience can
be misleading; at least one-third of
current patients should be randomized
controls.
If a clinical trial is simply designed to
* Compared to a 50: 50 randomization, 60: 40, 65: 35 or 75: 25 randomizations entail reductions in
the chance of obtaining a statistically significant difference which are approximately equivalent to the
reductions produced by eliminating 4%, 9% or 25% of the patients from the trial.
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discover whether a new treatment is
better than the standard treatment, and
to answer no other questions, the normal
practice is to randomise (1: 1 or perhaps
2:1) and to compare the fates of the 2
groups. However, some people prefer to
put all the patients on to the new treat-
ment and merely to see if they fare better
than previous " such " patients. The
advantages are that randomization, which
is sometimes difficult to explain to the
patient, is avoided; the group getting the
new treatment is bigger than it would have
been, since it now includes all the patients
who would have been controls; and that
the " control " group is bigger still,
comprising many other patients from
previous series. The overwhelming dis-
advantage is that there may very well be
systematic differences between the old
series and the treated series due to chang-
ing referral patterns to the study centre,
changes in supportive therapy, changes in
the skill of the doctors, or subconscious (or
even conscious!) selective biases: for
example, the omission of a few old or
moribund patients from the new series can
make a big difference to the overall out-
come.
Byar et al. (1976), in a readable paper
on this and other aspects of clinical trial
methodology, give a nice example of 2
large series of prostatic cancer patients,
selected by the same criteria at the same
centres, both given placebo yet differing
substantially in survival. Likewise, S.
J. Pocock has collected 19 unselected other
instances where consecutive trials in the
same malignant disease at the same
collaborating centres carried over a com-
mon treatment arm from one trial to the
next. The results when one arm was
compared with the supposedly identical
arm in a later trial were often materially
different; 10 of the 19 2-tailed P-values
were less than 0-2 (as opposed to 4
expected by chance), and 3 were less
than 0 02.
From the point of view of the reader of
a publication describing a clinical trial in
which a recent series is only compared
with previous experience, there should
always be grave suspicion that maybe
initially the 2 groups of patients were
systematically very different, or that the
treatments they were given also differed
in ways other than the treatment difference
which is claimed to be the only important
variable. (Changes in the standards of
supportive care, or in the ability to use a
potent drug successfully, can easily occur.)
A prudent reader would, perhaps, say that
the chance of a substantial systematic
difference due to conscious, subconscious
or accidental bias is at least 5 or 10%, and
so no P-value less than 0 05 can in
principle be obtained from such a study,
if by "P-value " we mean the proba-
bility of such results emerging if there
is no real difference between the treat-
ments.
Such studies can be of some value, of
course. If the new treatment cures almost
everyone who would previously have died,
historical controls may suffice to demon-
strate this adequately. Also, of the
P - 0-05 differences reported from the
hundreds of randomized trials currently
in progress, a good proportion are artefacts
of chance, and comparison with other
series can help sort out which are real.
If the randomized controls have fared a
lot worse than expected on the basis of
previous series, this is probably one of the
bogus significant results, while if the
randomized controls seem to have fared
ordinarily, the claim is more plausible.
This use of historical series to cast doubt
on current claims is most valuable, and
should be more widespread. Finally, a
physician convinced of the merit of a new
treatment cannot ethically randomize his
patients, and must use historical controls:
a proper function of his research might be
to convince any sceptical colleagues that a
large randomized trial should be under-
taken.
However, unless a trial is seen by the
investigators only as a " pilot " trial, a
precursor to a future randomized study,
it is probably wise to randomize, and
Chalmers (1975), in a delightful 3-page
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paper, argues that even pilot trials should
be controlled by randomization.
A reasonable compromise for someone
intent on a major study using only
" historical controls " would be (unless
the new treatment is so confidently
preferred that randomization is felt to be
unethical) to randomize in the ratio 2: 1.
Two-thirds of the patients are still avail-
able for comparison with whatever " his-
torical controls" are preferred, while
people who only believe results from
randomized trials have almost as sub-
stantial a randomized study to examine as
if the more ordinary 1: 1 randomization
had been adopted.
Inevitably, however, many situations
will arise where only historical comparisons
are available to a reader, and no large
randomized study will be available in the
near future. Since a common bias in
historical comparisons is the inclusion
in one series of more of the acutely ill
patients than in the comparison series
it may be of value to ask " Among the
survivors 6 months after entry in both
series, was there subsequently any
appreciable difference in survival?" and,
if not, to suspect strongly that the 2
series of patients differ not in efficacy
of treatment but rather in efficacy of
exclusion of the acutely ill from one series.
Comparisons with a delayed start such
as this are irrelevant if the new treatment
is chiefly concerned with an early acute
phase of the disease, but may be of
value in casting doubt on claims for treat-
ments which, if effective, would be
expected to be of continuing therapeutic
activity.
" Blind allocation ", in which the
patient is unaware of which treatment he is
receiving, and " double-blind allocation ",
in which both the patient and physician
are unaware, are sometimes excellent
devices for helping ensure that response is
assessed objectively, and whenever assess-
ment of the response of interest is subject
to much uncertainty it is worth consider-
ing whether the treatments could be
formulated effectively in ways which
appear indistinguishable to the patient,
the physician, or both. Alternatively,
" blind assessment " of a subjective
response by another physician, who really
is unaware of the treatment being given,
may be of value. A subjective response,
such as "disease stasis " or "escape
from disease stasis ", in solid tumour
therapy should either be avoided, or
assessed in as objective a manner as
possible.
11.-Treatment allocation
Balanced randomization at the latest
possible time is recommended, with
no stratification; Appendix 2 gives
practical details of how this is done.
At the start ofa trial, each participating
centre may be given an ordered set
of sealed envelopes. A preferable techni-
que is to keep the envelopes at a central
office and to make the separate centres
telephone for instructions when a new
patient is to be randomized. This uses more
administrative time, but it does avoid all
suspicion that any form of cheating has
occurred, and it leaves no doubt at the
central office about exactly who has and
who has not been admitted to the trial.
Each envelope contains the instruction as
to which treatment schedule to follow for
a particular patient. When a patient who
appears to satisfy the admission criteria
is found, he is formally admitted, and
only then is the envelope opened to dis-
cover his treatment.
If randomization is to be by reference
to a central office, a simple randomization
list may be constructed instead of a set
of envelopes, as long as this list, which
specifies the order in which treatments
will be allocated throughout the trial,
will never be seen by any physicians
responsible for patient entry, including
any trial organizers who also treat
patients.
If the treatment -to be given to the
next trial patient is known before the
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decision whether to admit him is made,
this decision may well be influenced by the
knowledge of what treatment he was to
receive. If this happens, the groups of
patients on the different protocols may
differ systematically, and consequently
the trial result may be of little value. It
is not permissible to enter patients and
then withdraw them from the trial if the
treatment allocated is felt to be inappro-
priate: once admitted, patients must be
followed up and included in the final
report of the trial. If any of the treat-
ments a patient might get are felt to be
inappropriate, give that patient whatever
treatment you think best, but don't
include him in the trial. In other words,
before randomizing a patient into a trial,
check that you would be prepared to
give him any of the treatments, that he
would be prepared to receive any of them,
and that there are no geographical or social
reasons which make any one ofthe possible
treatments impracticable.
In a randomized trial comparing 2
treatment schedules for patients whose
disease has first been controlled by
standard therapy, there may be an
initial period during which the treatment
a patient should receive is the same no
matter what schedule will eventually be
specified for that patient. For example,
in the MRC trial of immunotherapy for
myeloid leukaemia, the patients are first
treated by chemotherapy in order to induce
partial control of the disease: many
patients do not achieve such remission of
disease, but those who do are then
randomized between continued chemo-
therapy and continued chemotherapy
plus immunotherapy. Randomization
could occur when the patient is first
diagnosed, or at any time during the early
intensive phase which is common to all
patients, or not until remission has been
completely achieved. The advantage of
early randomization is that it is easier for
doctor/patient relationships if the doctor
knows as soon as possible how he will
treat his patient. The grave disadvan-
tage of early randomization is that un-
41
biased analysis of most such trials can
usually only be guaranteed if all deaths
occurring in either treatment group after
randomization count against that group-
even including deaths during the early
period, when patients in both groups
should be being treated identically! If,
therefore, randomization takes place well
before the patients in the 2 groups have
to be treated differently, chance differ-
ences in what happens in the early
(common) period may dilute real differ-
ences in the later period. Randomization
should, therefore, usually take place as
late as possible, and analysis should
preferably compare the totality of post-
randomization mortality in one group
with that in the other. These rules also
apply in clinical trials of whether to stop
regular anti-cancer treatment in patients
who have been apparently free of disease
for some time. It is preferable to count
the total number of post-randomization
deaths in each group, even if random-
ization occurred after slightly different
disease-free periods in different patients.
It is therefore generally preferable to
randomize as late as possible, so that
almost immediately after randomization
the patients in different groups will start
to receive different treatments. Like-
wise, in trials comparing different treat-
ments for the relapse of previously con-
trolled disease, wait until relapse actually
occurs before randomizing.
The order in which the treatment
schedules appear in the sealed envelopes
should ideally be:
(1) Unpredictable, in the sense that
the physician may know that the
overall ratio is 2:1, 1:1, 1:2 or
whatever, but given this, he has
no further idea what the next
envelope contains.
(2) Balanced, so that when the trial
stops, the numbers of patients on
the 2 treatments are roughly in the
desired ratio.
(3) In addition, it would be an
advantage if the patients with
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good and bad prognoses were also
each balanced in the same ratio
between the treatment groups.
A variety of allocation schemes can be
devised, ranging from simple coin tossing
to elaborate " stratification " schemes in
which a separate series of envelopes is
provided for each of several prognostic
categories of patient*. However, proper
statistical methods, such as those which
will be introduced later, make due allow-
ance when comparing 2 treatments for
what was initially known about each
patient. (This may be thought of as
" retrospective stratification ".) If pro-
per methods of analysis will be used,
stratified entry makes little difference, and
it is usually completely satisfactory to
have a single series of envelopes for all
patients, and not to bother to " stratify "
in any way. This is discussed further in
the next section. How should the
sequence of treatments in these envelopes
then be determined? The difficulty is
that, unless the numbers are large, the
requirements for (1) unpredictability and
(2) balance are to some extent incompat-
ible. Because of this, some statisticians
say " Randomize: that's the only way to
achieve complete unpredictability " (which
is true), while others (like us) say:
" Constrain the randomization to keep the
proportions allocated to the 2 groups
reasonably close to your chosen pro-
portions." (Statistical Note 2, on p. 611,
discusses, but does not recommend, other,
more complex, allocation rules.) The
disadvantage of randomizing if your
chosen proportions are, say, 1: 2 is that
you may end up analysing a very lopsided
trial with 5 out of 30 on one treatment
instead of an intended 10 out of 30.
For this reason, complete randomization
should not usually be used, unless the
intended allocation ratio is 1: 1, in which
case it is fairly safe, even though pseudo-
randomization may still be preferred:
see Appendix 2. The disadvantage of
pseudo-randomization is that the
physicians may see through the scheme,
work out the next treatment, and so
admit different types of patient to the
2 treatments, but we have never known of
this happening.
The practical details of both methods
are trivial: to produce 100 envelopes
randomized in the ratio 1: 1, you toss a
coin 100 times, getting a series of letters
A (for heads) or B (for tails), and then you
make up the envelopes in the order
specified by your list, keeping the list to
check that the physicians use the envel-
opes correctly and obey them. To pro-
duce 100 envelopes pseudo-randomized
in the ratio 2:1, 1:1 or 1:2, you may use
the methods described in Appendix 2.
In a multi-centre trial, it is slightly
preferable to have a balanced allocation
list (see Appendix 2) for each separate
centre, especially if the number entered
by some centres is very small. This form
of stratification involves no extra trouble
whatever for the participating centres,
and actually helps maintain their interest,
by ensuring that each centre is called on
to administer each treatment.
12.-Should " 8tratifted " allocation be en-
visaged?
If, during analysis, initial prognosis
will be allowed for while the different
treatments are being compared, there
is hardly ever need for stratification
at entry in large trials.
As long as good statistical methods,
such as those given in Part II of this paper,
are used to analyse data from clinical
trials, there is no need for randomization
to be stratified by prognostic features.
Moreover, if the organizational complexity
of it deters any collaborators from entering
patients during busy clinics (or deters
* If each of these separate series of envelopes is completely random, no improvement in balance what-
ever is obtained by such " separate randomization ": the treatment prescriptions in each particular such
series of envelopes must therefore alternate, or have some other such constraint imposed on them, if
stratification at entry is to have any effect whatever.
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them completely from collaboration in
this or in some future trial), positive harm
will have been done by the initial strati-
fication. These views are not generally
accepted, so in this section we argue them
at greater length than many readers will
wish to follow. If you agree that strati-
fied randomization is usually unnecessary
(except, perhaps, in very small trials),
or if you are indifferent on the matter, skip
this section.
Usually, for purposes of statistical
analysis, the patients will be subdivided
into a few strata, defined retrospectively
from those features (e.g. age or stage) which
are eventually found to be really relevant
to prognosis. The points of subdivision
of each such feature can be chosen in the
light of the actual data, to make the
prognostic discrimination most sharp, and
certain groups with a similar prognosis
may finally be merged. The patients
within one stratum will then be com-
pared with each other, to see if treatment
appears to have been beneficial, and the
comparisons within each stratum will
finally be combined to give a single overall
P-value for the effects of treatment
adjusted for initial prognosis (see Appen-
dix 3 in Part II for a worked example).
If the distribution of treatments is
similar in each stratum, no actual bias is
corrected by such " retrospective strati-
fication ", but the fact of comparing like
with like makes such an analysis slightly
more sensitive. Suppose now, that we
stratify at entry, randomize with " bal-
anced " random numbers within each
initial stratum (or assign treatments by
alternation within each stratum), and
suppose further that, by luck and good
judgement, the initial strata are all
subsets of the retrospective strata which
we devise during the eventual statistical
analysis of the data. Retrospective strati-
fication will still have to be undertaken,
for if no allowance is made in a statistical
analysis for the fact of stratified entry, the
calculated P-values are not extreme enough.
The only advantage gained by stratifica-
tion at entry is that, within each retro-
spective stratum, reasonable balance
between the numbers on each treatment
will automatically be achieved, and a
wasteful situation, where almost all the
patients in one retrospective stratum
happen to get the same treatment, is
avoided. This advantage, however, is
largely illusory, unless the trial is very
small. The improvement in the sensi-
tivity of a clinical trial to be expected
from achieving perfect balance between
the numbers on each treatment in each
restrospective stratum, instead of letting
them be defined by chance, is just that to
be expected from randomizing a single
extra patient into each retrospective
stratum. (This is proved in Statistical
Note 3 on p. 611.) However many
initial strata are defined, only a few
retrospective strata will be needed, and
so the expected benefits from initial
stratification are- slighter than would
intuitively be expected; indeed,- if the
organizational complexity of stratification
at the time of randomization reduced
collaboration at all, a net loss of efficiency
would be the likely result. This objection
does not, of course, apply to sttatification
by centre in a multi-centre trial.
13.-Exclusions, withdrawals, losses, and
deviations from treatment
Rigorous entry criteria are not neces-
sary for a randomized trial, but
rigorous follow-up is. Even patients
who do not get the proper treatment
must not be withdrawn from the
analysis.
Individual physicians will probably
have, for certain of their patients, a
definite preference for one or other (or
none) of the trial treatments. When this
happens, the patient cannot ethically be
admitted to the trial in case he gets the
" wrong " treatment: he must be ex-
cluded from the trial, and be given the
treatment thought best for him, even if
there is little objective basis for this
preference.
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It is worth including in the trial
protocol specific instructions against ran-
domizing patients who are unlikely to
tolerate, or who may be unable to receive,
any of the treatment schedules (e.g.
through having " bad " veins, and thus
not able to receive prolonged i.v. therapy),
who are extremely old or extremely young
for the disease, who seem unlikely to
cooperate, who live so far away that
regular treatment will prove difficult, or
whose disease seems likely to take an
abnormal course. Certain of these
patients may teach one a lot about the
disease, but not through inclusion in a
clinical trial. Also, if the disease process
is very long, it is best to restrict admission
to patients who are likely, as far as one
can tell, to continue to attend the same
hospital throughout the course of their
disease.
It is also best to restrict collaboration
to centres thought likely to continue to
collaborate seriously for a few years, for
if, in a multi-centre trial, some centres lose
interest during the first year and start
giving trial patients all sorts of different
treatments, or stop supplying the
necessary follow-up information, the re-
sult can be progressive collapse of the
whole study. This may be preventable if
deviant centres are quickly expelled
or quickly asked to reform, but this
requires up-to-date monitoring of the
study by a group with some moral
authority.
In a clinical trial, there are 3 distinct
categories of missing patients: those who
are excluded before randomization;
those who, despite having been random-
ized, are deliberately withdrawn from
the trial as though they had never been
entered; and those who are inadvertently
lost during follow-up, and whose experience
can be included in the statistical analysis
only up to the date of loss. There is no
agreed terminology for these 3 categories,
and we will refer to them as exclusions,
withdrawals, and losses, respectively (see
Fig. 2).
13A.-Exclusions.
Exclusions, whether for serious reason
or a whim, do not bias the randomized
treatment comparison (in fact, they do not
enter into it at all), and they are therefore
acceptable under all circumstances. It is,
however, preferable to define roughly the
No bias is-caused
by exclusion, even
if for silly reasons
Severe bias may arise
if protocol violations
can affect the
decision to withdraw
Bias may arise if
A and B, by differing
in unpleasantness,
toxicity or efficacy,
affect loss differently
FIG. 2.-Exclusions, withdrawals, and losses.
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reasons used for exclusion and inclusion,
so that other workers can judge your
average results and compare them with
other series.
The participating centres may agree
to make a list of every patient presenting
at that centre with the disease being
studied, noting whether that patient was
randomized and, if not, why not. Such
lists may help characterize the patients
being studied in the trial, which may be
useful but is not logically necessary in a
randomized study. Such lists may also,
perhaps more importantly, help prevent
the rate of entry falling off as enthusiasm
wanes or staff changes occur at the
various centres.
13B.-Withdrawals.
Sporadic losses and, particularly, with-
drawals can bias the results, and adopting
an explicit policy towards withdrawals
and losses should be part of the design
stage of a trial. One excellent policy is to
accept no withdrawals under any circum-
stances. This may not be satisfactory,
however, if the differential diagnosis of
the disease is difficult. For such diseases,
it may be best for the information
collected from each patient at the time of
randomization to be reviewed centrally, in
ignorance of the treatment schedule to
which the patient was allocated, so that
patients thought at this central review
not to satisfy the agreed trial criteria can
be withdrawn as if they had never been
entered, without in any way biasing the
treatment comparison. If the initial diag-
nostic tests are known always to yield,
when results eventually emerge from
them, simple unequivocal yes/no results,
then it would be acceptable to include in
the trial design the instruction that the
diagnostic test should be done at random-
ization for every patient (or at least for
every patient for whom the differential
diagnosis is uncertain), and that when the
results become available those patients
tested at randomization and found to have
the wrong disease should be withdrawn by
the responsible physician, with no refer-
ence to the trial secretariat.
If there is to be a central blind review,
it may actually take place long after
randomization; indeed, there is some
advantage in reviewing a large number of
the patients simultaneously to ensure
uniformity of judgemopt. If the review
occurs after the trial has closed, all
patients can be reviewed together.
In the foregoing rules (which should be
adopted whenever possible), observations
made at the time of randomization are
used to determine without bias who will be
withdrawn. Unfortunately, for example,
acute undifferentiated lymphoblastic leu-
kaemia might be mistaken for myeloid
leukaemia by all criteria that can be
recorded at presentation, and the mis-
diagnosis might not be recognisable until
partial control of the disease has been
achieved. The previous rules will not
then apply, and there are then only 3
options for the design of such trials:
(1) Do not randomize patients unless
or until the differential diagnosis
is unequivocal. (This may lose
some appropriate patients from the
study.)
(2) Randomize some or all of those in
whom the diagnosis is doubtful,
withdrawing any who sub-
sequently proved to have the
wrong disease as if they had never
been randomized.
(3) Again, randomize some or all of
those in whom the diagnosis is
doubtful, but leave all random-
ized patients in the final analysis,
even those whose diagnosis was
revised and whose treatment con-
sequently altered. (This is always
valid, and is sometimes the only
valid policy, but it is somewhat
artificial.)
Option (2) is medically preferable, as long
as it is statistically valid, and it is more
widely valid than most statisticians
believe. It is true that, if one treatment
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keeps patients alive longer than the other
treatment does, then there may be more
opportunity for diagnostic revision and
hence withdrawal, but this is unlikely to
completely obscure the merits of the better
treatment. What determines whether (2)
is acceptable therefore depends chiefly on
what might be expected if the two treat-
ments have equivalent effects on survival
duration. In this case, (2) is only invalid
if the different treatments will affect the
probability of diagnostic revision dif-
ferently, and this will be the exception
rather than the rule.
Whatever rules are adopted to deal
with the problem of possible misdiagnosis,
they should be written into the design of
the trial and not invented ad hoc during
the statistical analysis to exclude an
unwanted patient or two from a particular
group.
13C.-Losses and deviations.
Patients who move away from the
centres where they were admitted to the
trial should not be allowed to disappear
from the trial. If possible, their fate
should be discovered, perhaps by extensive
telephone enquiries, letters, or even special
visits by research assistants. (The MRC
leukaemia trial policy is to accept no
reason, other than permanent emigration
from Britain, for loss, and so they try to
avoid including foriegn nationals in their
trials.)
It is sometimes suggested that if a
substantial deviation from the allotted
treatment occurs, that patient should not
be included when the final comparison of
treatments occurs (or should be included
only up to the date of deviation). This is
seriously wrong, as the group which devi-
ates from one protocol and the group
which deviates from the other protocol
may be so different in their chances of
long survival that the treatment compari-
son in the remaining patients will be
severely biased. Disagreement about this
point is perhaps the chief source of mis-
understanding between statisticians and
clinicians about the logic of trial design.
To clinicians who disagree, it might be
pointed out that including all the deviants
can only affect the conclusions appreci-
ably if the deviants are more numerous in
one treatment group than in another, and
grossly different in survival duration
from the protocol adherents, but in this
case exclusion of them is not valid.
Withdrawing protocol deviants from the
statistical analysis is therefore either
irrelevant or invalid in large trials.
A serious error is to exclude from the
statistical analysis any post-randomiza-
tion, pre-treatment deaths in the active
treatment group, while retaining all the
untreated controls. The safest general
rule is always to leave all randomized
patients in (and to randomize later in
your next trial!) for in a large trial the
overall results will only be materially
affected by exclusions if there is a dis-
crepancy between the numbers of ex-
clusions in the two treatment groups
which is so marked that it suggests their
exclusion was invalid.
13D.-Example: retaining deviants.
This has arisen recently in the MRC
trial of elective splenectomy in chronic
granulocytic leukaemia. Patients with
chronic granulocytic leukaemia are
randomized to be either splenectomized
or not when their disease is in remission.
Unfortunately, some of the no-splenec-
tomy group may later develop splenic
symptom's which call for splenectomy, and
so a few of the patients randomly allocated
to no-splenectomy may in fact be
splenectomized! Those allocated to the
no-splenectomy group who actually seem
to need (and therefore get) splenectomy
are unlikely to live as long as average,
so if we excluded them or if we transferred
them from one group to the other group,
the 2 groups would no longer be com-
parable.
The simple comparison of all patients
actually splenectomized with all truly
non-splenectomized patients is not a valid
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measure of the value or otherwise of
elective splenectomy, as these 2 categories
were not separated from each other at
random. Neither is a comparison of the
group which was randomly allocated for
splenectomy with the group which was not
splenectomized valid. We must not treat
any patient as lost even if that patient
has to be splenectomized later on. We
must follow all of them to death or to the
end of the trial, and then compare the
group which was randomized to splenec-
tomy with the group which was random-
ized to no-splenectomy, whatever sub-
sequently happened to them. This
answers the medical question of primary
interest, which is whether a policy of
splenectomy, if medically possible, is
superior to a policy of no splenectomy
unless specifically indicated.
When departures from protocols are
necessary, clinical trials compare a policy
of one treatment as far as possible with
another policy, and although it is often of
interest to describe the results among the
protocol adherents, comparisons which
omit protocol deviants cannot be tested
statistically.
14.-When to analyse and publish your
results
Early analysis of a trial can be mis-
leading if a temporary difference,
which would have been smoothed out
by large numbers, causes the trial to
be aborted so that large numbers
never accumulate.
Most statistical tests applied to clinical
trial data are based on the assumption,
usually false, that the decision to stop and
publish has been taken completely in-
dependently of the current results. This
is true of the methods we will describe,
and of the methods used in almost all
published reports of trials. However,
only an investigator with superhuman
willpower or completely chaotic records
could supervise a clinical trial for months
or years without ever looking to see which
way the results were drifting, and in
practice every now and then at least a
cursory impression is usually sought. If
no striking difference is apparent, the
trial may tick on, but if there is an
apparent difference a more formal
analysis will be undertaken, and if this is
positive, the trial is likely to be stopped
and its results published.
Suppose you look every 6 months at a
3-year trial that is comparing treatments
which are really equivalent, and ask on
each occasion, "Is it significant at the
0 05 level yet?" The chance that it will
be on any one particular occasion is 0 05,
but unfortunately the chance that it will
be on at least one of the 5 occasions is
much more than 0.05. If your policy is to
look every 6 months and publish if you
ever find P < 0.05, then the chance that
you will publish a " significant (P < 0.05)
difference " in a trial comparing 2 treat-
ments which are, in fact, identical is
probably more like 15% than the 5%
which is claimed, and for this reason,
most published P-values should be men-
tally doubled or tripled (McPherson, 1974).
Statistical theory can, by standard
methods, compute a P-value on the
assumption that no preliminary exam-
ination occurred, and statistical theory
can, by " sequential " methods, compute
a P-value on the assumption that very
frequent preliminary examination has
occurred, with the intent of stopping the
trial when a given difference was reached.
(Particular sequential methods for cancer
trials are discussed in Statistical Note 4
on p. 611.)
Unfortunately, statistical theory can-
not in principle compute a P-value from a
trial in which occasional preliminary
examination occurred: one can only say
that the true significance level must be
less extreme than the cited P-value, but
not as much less extreme as it would have
been had very frequent preliminary exam-
ination occurred.
This present state of affairs is not
satisfactory, and no easy universal
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solution exists. One simple rule, that will
often help considerably, is to avoid any
analysis (or even brief inspection) of the
data until some dozens of deaths have
accumulated, for it is trials first looked at
when very small that are most likely to be
misleading. Eventually, the fear that
one treatment may be vastly worse will
compel inspection, but the longer the
delay before first analysis, the smaller the
risk of a misleadingly significant difference
being discovered when the treatments are
really equivalent.
The simplest solution is to continue as
at present, where most published P-values
need to be mentally doubled. The only
completely ethical and valid alternative
is for every clinical trial to have a pro-
fessional statistician, using weekly com-
puterized analyses to administer a sequen-
tial design. Because the present article
is intended to enable clinicians to design
and analyse their trial, without getting tied
up in statistical knots, we shall ignore the
possibility of using sequential methods,
(except for those suggested in Statistical
Note 4) and shall describe instead the
straightforward, non-sequential analysis
of ordinary clinical trial data, despite the
drawbacks outlined above.
15.-Ethical considerations
Individuals must never be denied
clearly appropriate treatment, even if
trial protocols are thereby disrupted.
Physicians who are convinced that one
treatment is better than another for a
particular patient of theirs cannot ethic-
ally choose at random which treatment to
give: they must do what they think best
for the particular patient. For this
reason, physicians who feel they already
know the answer cannot enter their
patients into a trial. If they think,
whether for a wise or silly reason, that they
know the answer before the trial starts,
they should not enter any patients, and if
they become convinced that one treat-
ment is better during the course of the
trial, they must stop randomizing their
patients.
To avoid trials grinding to a halt before
any marked degree of statistical signifi-
cance has been obtained, Chalmers has
suggested that it may be necessary to
keep the treating physicians ignorant of
the current state of the treatment com-
parison, and only to allow access to the
pooled results from all the centres to a
small steering committee which decides
when the trial shall stop, giving no pro-
gress reports whatever on the results
until after the trial intake has been halted.
(An intermediate alternative, routinely
used by Zelen and his colleagues, might
sometimes be to give progress reports,
with outcome tabulated by treatment,
but keeping secret which treatment is
which.) The ethical considerations of the
supervisory committee can then be guided
by slightly wider perspectives than the
treating physicians, balancing the damage
done by an inconclusive result against the
damage done by continuing to allocate
some patients to a schedule which appears
at the time to be suboptimal. Such a
policy has not been adopted by the MRC
Leukaemia Steering Committee, partly
because so few of our trials have dis-
covered any differences, but we may some
day have to do so.
This is not an easy matter: any trial
which produces good evidence that one
treatment is better than another would
have produced almost as good evidence
had the last patient given the inferior
treatment actually been assigned to the
other treatment. If the developing trend
is already appreciated by the physician
before this last patient is randomized, how
can allocation to the inferior treatment be
justified? Continuation of this argument
suggests that serious consideration of each
individual patient's welfare will lead to
policies which prevent any clinical trial
from producing a clear answer,* which,
* Unless response is so slow that admission of all patients is complete before the results emerge.
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paradoxically, will be policies detrimental
to the very people they are designed to
protect. An ethical imperative exists
which is frequently ignored, that we must,
if we can, discover how patients can be
treated most effectively, and where this
requires randomized trials, the apparently
irrelevant device of keeping the physicians
ignorant of the current results just
manages to avert the previous paradox.
(Another device which can, in slow
diseases such as cancer, help avert it, is to
make total entry as rapid as possible, so
that entry is finished before any trends can
be seen.)
" Blind " trials, where the patient, the
doctor, or both, are unaware of which
treatment has been given, are frequently
easier to organize if placebo treatments are
given to the control patients. It is
doubtful whether any invasive placebo
treatments, involving, for example,
dummy injections or infusions, are justi-
fiable, unless a very unusual degree of
informed consent has first been given, and
the same applies to diagnostic surgery,
X-ray investigations, and to bone-marrow
(or other) aspirations, if these are of no
value to the individual patient.
Finally, of course, it may be ethically
necessary not to adhere to a trial schedule
which is clearly unsuitable for a particular
patient, even though this slightly muddies
the scientific comparison of schedules
with each other, by diluting one group
with people who did not receive the
scheduled treatment. In all trials,
clinicians must tread a narrow path
between unnecessary deviations from
protocol and the risks that the protocol
may have for the exceptional patient.
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APPENDICES
APPENDIX 1.-The Relationship Between
Numbers and Sensitivity
It is possible for a clinical trial comparing
2 treatments to produce a " statistically
significant " (P < 0 05) difference even if the
treatments are, in fact, equivalent in their
effects. A far more common mishap is for a
comparison of 2 treatments which really are
different to fail to reach statistical significance.
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However, if there really is a difference
between the chances of survival under the 2
treatments, the more patients we put into
the trial the more likely we are to get a
statistically significant difference, and this
Appendix indicates the approximate numbers
of patients that must be randomized to have
an even chance of a statistically significant
outcome when the trial is finally analysed.
Of course, the numbers required depend on
how big the true difference is, and if you knew
that at the design stage you would not be
doing the trial anyway! However, in prac-
tice, physicians usually have an idea of what
differences might well exist between 2 treat-
ments, and this Appendix is intended to be
used to ensure that ridiculously small trials
are not started (see also main text). Unless
you can say " such-and-such a difference
might well exist, and if it does we have a
better than even chance of detecting it ",
you should not start a clinical trial.
Approximately equivalent numbers are
usually needed for a null trial result to be
useful. Suppose that, in a trial sufficiently
large for a given difference to have an even
chance of being detected, the 2 groups
eventually fare about the same as each other.
You will be able to conclude (with " 95%
confidence ") that the real difference could
be zero and could be anything up to that
given difference in either direction, but that
the real difference could hardly be any more
extreme than this. If, therefore, that given
difference was one which you had previously
thought might well exist, your null trial has
told you something new, but otherwise it has
not.
To use this Appendix, first estimate
roughly how many patients you will be able to
randomize, and roughly how many of these
will die before the trial is analysed. This is
because the sensitivity of a clinical trial
depends not so much on the total number of
patients randomized into the trial, but rather
on the number of patients who die before the
statistical analysis takes place. Next, refer
this projected number of deaths to Table II
to see what magnitude oftreatment differences
you are competent to characterize. The
calculations leading to this table need not be
understood, but the conclusions it expresses
must be.
For a given degree of superiority of one
treatment over the other, Table II indicates
the number of patients that must die in a
clinical trial for there to be an even chance of
a statistically significant difference being
observed. Even if the observed difference is
not statistically significant, however, it is
still likely to be in the right direction (and
likely to be nearer being significant than to
being zero) and thus, it will probably suggest
the correct answer. If the trial size is
doubled, the chance of statistical signifi-
cance rises from 50% to 80%, and even
if statistical significance is, unfortunately,
missed, there is almost bound to be a sub-
stantial difference in the right direction.
Example-If we expect an average intake
of 2 acute myeloid leukaemia patients a week,
and we expect about half the patients to die
within 6 months of entry, half the survivors
to die within the next 6 months, etc., then
what sensitivity could we expect from a
clinical trial, the intake to which lasted one
year?
Answer-By the time entry is complete,
one year afterentrystarted, about 100 patients
will have been randomized, and we might
find that about 40 of these patients will
already be dead. If we analyse immediately,
column (b) of Table II tells us that we have
an even chance of detecting an improvement
from 50% dead within 6 months of random-
ization to 30% dead within 6 months, but
that we are unlikely to detect any less
striking differences. If, however, we delay
our analysis for a year or two, until most of
our patients have died, we will have observed
about 100 deaths and would have an even
chance of detecting an improvement from
50% dead within 6 months of randomization
to 37% dead. Again, however, any less
extreme improvements are likely to elude
us.
APPENDIX 2.-Detailed Instructions for
Preparing " Balanced " Randomization Lists
Balancing the allocation numbers at
intervals ensures that no time trend in the
allocation ratio will exist, and so no bias can
arise, even if a time trend in the prognoses of
the patients exists for any reason.
One way of pseudo-randomizing in the
ratio 1: 1 is to make sure that the ran-
domization balances at every 6th patient.
This can be done by numbering the 20
possible different sequences of 3 A's and 3 B's
as follows:
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Number Sequence Number Sequence
00-04
05-09
10-14
15-19
20-24
AAABBB
AABABB
AABBAB
AABBBA
ABAABB
25-29
30-34
35-39
40-44
45-49
ABABAB
ABABBA
ABBAAB
ABBABA
ABBBAA
You then select one 2-digit number at
random (e.g. by shutting your eyes, marking
the Random Number Table (Table III)
haphazardly with a pencil point, and then
starting with the number nearest to the mark
thus made), and read off the series of 2-digit
numbers from there on. Replace each such
2-digit number by the corresponding letter
sequence and use the overall sequence of A's
and B's thus generated to specify the order
of the contents of your randomization
envelopes.
A similar approach to 3-group trials is
possible; in order to get a random ordering of
2 A's, 2 B's and 2 C's, proceed as above but,
having selected one of the above sequences,
use the next 2-digit random number to change
one of the A's and one of the B's into C's, as
follows:
Number Sequence Number Sequence
50-54
55-59
60-64
65-69
70-74
BAAABB
BAABAB
BAABBA
BABAAB
BABABA
75-79
80-84
85-89
90-94
95-99
BABBAA
BBAAAB
BBAABA
BBABAA
BBBAAA
If you have to prepare one randomization
list for each of several centres, the easiest way
is to produce a single list of the appropriate
length for one centre, and then to start at a
different place on it for each different centre,
retuming to the top of the list again when-
ever you reach the bottom of it.
Multiple randomization (answering 2 or
more questions with one clinical trial). Sup-
pose you wish to answer 2 questions, one of
which is answered by comparing treatment
A with treatment B, the other question being
answered by comparing treatment ax with
treatment P. Prepare 3 independent, sepa-
rate lists: one for randomizing A versus B,
the second for randomizing the A's between
cx and P, and the third for randomizing the B's
between ca and ,B. If the decision between cy
Next no.* Change into C
01-11 First A,
First B
12-22 First A,
Second B
23-33 First A,
Third B
* If 00 arises, ignore it and proceed to the next 2-digit random number.
Finally, a similar approach to random-
ization in the ratio 2:1 or 1:2 is possible:
simply produce a balanced sequence of A's,
B's and C's as above, and then either change
all the C's to A's (for a 2:1 sequence) or
change all the C's into B's (for a 1: 2 sequence).
Example-If the mark made by your
pencil is nearest to the number 33 in the
3rd row of Table III, the numbers obtained
will be 33, 16, 26, 91, 57, 58, etc., giving:
and does not need to be taken until some
time after the decision between A and B has
been taken (e.g. ifA and B relate to induction,
while ca and relate to maintenance) keep the
lists separate, and do not randomize between
ax and ,B until you have to. If the decisions
all need to be specified at the same time, the
lists can all be combined (by running down
the A's on the first list and writing ax or ,
beside each according to the second list, and
Rtaiilnom Number
1: 1 SequenIco
1:1: 1 Seqluelnce
2: 1 Se(qulenlCe
1 : 2 SeqenLCe
33
ABABBA
ABA$BA
C C
16 26
AABBBA ABABAB
ABAB4$
CC
CBACBA
ABAABA
BBABBA
91 57
BBABAA BAABAB
BAABA$
C C
ABABCC
ABABAA
ABABBB
58 ...
BAABAB
...
BACBAC
...
}3AABAA ...
BABBAB
...
Next no.
34-44
45-55
56-66
Change into C
Second A,
First B
Second A,
Second B
Second A,
Third B
Next no.
67-77
78-88
89-99
Change into C
Third A,
First B
Third A,
Second B
Third A,
Third B
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TABLE II.-Approximate Sensitivity of Clinical Trials with a Given Total Number of
Deaths at the Time of Analysis of the Results, among Patients Randomized
Equally between 2 Treatments
Approximate Conditions for an Even Chance of Obtaining a
Statistically Significant Result:
Total no. of patients al-
ready dead at the time we
analysed the trial. (Far
more patients must be
randomized to observe
these numbers)
1200
500
200
100
40
20
10
(a) If less than half the patients
will die and the ratio of the
death rate on the better treat-
ment to that on the worse is as
stated below:*
Better :Worse
8:9
5:6
3:4
2:3
1:2
1:3
1:6
(b) If half or more of the patients
will die, and the chance of death
on the better treatment by the
time when half the patierit on the
worse treatment are dead is as
stated below :*
0-46
0-44
0-40
0- 37
0-3
0-2
0-1
* For a mathematical definition of columns (a) and (b), see Statistical Note 5 on p. 612.
then running down the B's according to the
third list). If 3 questions are being answered
a further 4 extra lists must be prepared,
randomizing between the third pair of treat-
ments for each of Acx, A,B, Ba, and BP. If
treatment A really is better than treatment
B, its relative merits will by chance show up
more clearly either among the ce-treated
patients or among the fl-treated patients, and
balancing the proportion of a's and P's in
groups A and B helps ensure that a simple
benefit of A is not confused with a benefit of
A only if a is also given.
STATISTICAL NOTES
These are collected together so that they
can be completely ignored by the non-
statistical reader. The statistical methods
recommended in this paper are developed in
Kaplan and Meier (1958), Mantel (1966),
Peto (1972), Cox (1972), and Peto and Pike
(1973), and are reviewed by Breslow (1975).
STATISTICAL NOTE 1.
(From Table I.) Most investigators have
a few cursory glances (or even full analyses)
comparing their 2 treatment groups while the
trial progresses, and if a significant difference
is noticed the trial is likely to be stopped and
published. This leads to some trials, which
would have been non-significant if interim
inspection had been avoided, actually being
published as smaller " significant " results.
Such practice increases the number of mis-
leading claims of significance by a greater
TABLE III.-Random Number Table
37
82
49
16
32
04
73
68
35
84
50
92
46
68
46
46
19
78
58
74
00
11
91
26
58
28
77
95
86
36
39
26
15
48
17
56
29
00
59
13
45 98
18 61
53033
96 54
39 19
32 13
64 75
47 25
81 16
58 05
55 92
49 54
51 60
22 40
51 03
76 29
49 58
32 86
55 87
71 00
54
90
16
11
54
45
19
69
29
10
28
50
31
17
73
48
67
74
11
71
52
90
26
01
56
59
05
11
37
70
28
41
55
43
99
33
08
78
74
24
89
63
91
96
57
03
61
90
60
50
89
21
27
25
89
87
56
55
06
41
26
78
57
58
23
91
11
26
39
31
64
06
84
33
28
70
27
55
49
67
34
57
58
81
58
08
64
19
35
04
87
62
14
31
44
79
24
72
46
62
40
32
42
37
24
69
31
07
05
12
80
73
71
26
16
03
20
58
31
38
71
61
81
10
14
35
07
27
95
12
35
86
02
44
08
61
67
23
89
84
11
05
89
24
28
41
89
59
98
95
23
33
82
46
77
59
70
09
40
95
41
66
42
90
33
17
36
15
45
72
06
95
96
34
07
37
18
08
26
66
82
18
34
84
43
89
87
58
52
72
68
73
23
96
19
08
01
79
39
42
79
76
00
22
01
87
98
19
27
81
52
80
16
32
94
08
67
18
74
90
13
06
48
97
87
24
75
48
24
67
00
91
58
26
87
80
70
54
94
92
60
39
51
80
77
84
49
83
49
74
84
35
94
59
56
96
46
76
86
39
38
95
05
98
36
44
38
59
00
01
53
05
71
34
16
81
31
07
66
26
08
75
48
72
20
42
96
90
29
72
97
21
48
99
56
79
04
53
66
30
86
94
27
81
97
83
60
95
07
90
97
37
35
00
09
68
32
73
97
29
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proportion than the number of right claims
is increased, and it affects the reliability of
claims of statistical significance in reports of
small (i.e. curtailed) trials much more than
in reports of large trials (i.e. nearing comple-
tion). This accentuates the conclusion, al-
ready suggested by the last column in
Table I, that significant results in small trials
are often wrong.
The above considerations apply to that
large majority of studies in which there is no
real difference or only a moderate real
difference, so small that it is likely to be
missed by a small trial. However, in those
few studies which compare treatments so
enormously different that a small trial is
likely to detect this, opposite conclusions
apply: such trials will necessarily stop when
still small, and such differences will therefore
only be found among significant small trials.
Proper treatment of this whole question
requires that a distribution of real differences
be postulated, and its consequences con-
sidered; as long as this postulated distribution
has a large majority of real differences so
small that they are unlikely to be detected
by small trials, the conclusions stated in the
main text remain valid.
STATISTICAL NOTE 2.
(From p. 600.) An alternative some-
times suggested is to vary the probability of
allocation of the next patient to each treat-
ment, in the light of the data so far, to make
allocation to the apparently better treatment
progressively more probable. If, however,
there is a tendency for later patients to fare
better irrespective of treatment, then data-
dependent allocation will produce too many
extreme P-values comparing treatments
which do not really differ, while ifthe opposite
time trend exists, a real superiority of one
treatment may be masked. The much larger
disadvantage is the possibility of conscious
or subconscious cheating in the selection of
patients for the trial. At the end of such a
trial, the physicians will know that their
favourite treatment is doing well, that most
new trial patients will now receive it, and that
if just a few more patients put on it now do
well, the trial will appear conclusive. Severe
bias is an obvious possibility, either for the
treatment or, leaning over backwards to be
fair, against it.
Another disadvantage is that such designs
may not be as acceptable to physicians as
simple randomization is, partly because the
underlying ideas will not be clearly under-
stood and partly because it may prove
difficult to convince some physicians, worried
about mistreatment of their patients, that
the current results justify a substantial
decrease in the proportion allocated to the
seemingly inferior treatment but do notjustify its abandonment.
STATISTICAL NOTE 3.
(From p. 601.) Statistical power depends
on the triple product of the size of a stratum
and the proportions on the 2 treatments.
These proportions may either be fixed or
binomial; the product, ifthey are fixed, equals
the expected product, if they were binomial
in a stratum containing one extra patient.
STATISTICAL NOTE 4.
(From p. 605.) Sequential use of the
logrank test is described in Chapter 7 of the
2nd edition (1975) of Sequential Medical
Trials by P. Armitage. (The 1st edition does
not contain such methods.) The advantage
of sequential analysis is the guarantee that in
the rare cases when one treatment is much
worse, the trial will automatically be aborted.
However, the advantage of not looking at the
results until the last minute is that if, as is
more usual, one treatment is only moderately
worse (e.g. if the better treatment only
reduces the death rate by 50% or less), a
statistically significant difference is more
likely to emerge than if sequential methods
had been used.
These advantages might be combined by
a policy of not stopping prematurely, unless
the chi-square comparing treatments reaches
some rather extreme value such as 9 (referring
to Armitage's " Repeated Significance Test "
designs for the P-value if it does). Other-
wise, let the trial run on to a previously
agreed final size or date, when ordinary
statistical analysis is undertaken. (Correc-
tion of the final P-value for the stopping
policy is possible, but would usually be
unnecessary.) This policy would be pecu-
liarly appropriate for cancer trials, where
prolonged follow-up is usual: here, the
monitoring would usually be needed only
while new patients were still being random-
ized, since, once this phase is complete, the
ethical difficulties of continuing to accumulate
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follow-up information may be less acute
(unless patients could still, with advantage,
be switched to the superior treatment late
in the course of the disease).
STATISTICAL NOTE 5.
(From Table II.) The death rate among the
survivors of a group will in general vary
according to how long ago randomization
occurred (since an exactly exponential dis-
tribution of survivorship is unusual). If, in
2 groups, the death rates vary in parallel,
that in one group among the survivors at a
given time after randomization being a
constant multiple A of the corresponding
rate in the other group, then we have a
" Proportional Hazard " situation (Breslow,
1975). If a 2-tailed 95% significance test
of the null hypothesis is performed between
2 such groups, using a logrank test, it is more
likely to be significant if A is markedly
different from unity or if the numbers are
large. Table II quantifies this: if, in column
(a), the ratio of Better/Worse is A, column
(b) gives 1 (O5)A.
If A is constant and is approximately,
but not exactly, unity, then the logrank
test is more likely to detect the difference
between the 2 groups than any other un-
biased rank-invariant test procedure is, and
is asymptotically fully efficient. (By con-
trast, Peto and Peto (1972) noted that no
class of differences exists against which
Gehan's (1965) generalization of the Wilcoxon
test is asymptotically efficient.) Of course,
even if the Proportional Hazard is not
appropriate, the logrank test is still a valid
test of the null hypothesis.
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